Edwards Lifesciences Corporation (NYSE:EW) went up by 0.68% from its latest closing price compared to the recent 1-year high of $87.79. The company’s stock price has collected -1.14% of loss in the last five trading sessions.
Is It Worth Investing in Edwards Lifesciences Corporation (NYSE :EW) Right Now?
Edwards Lifesciences Corporation (NYSE:EW) scored a price-to-earnings ratio above its average ratio, recording 71.81 x from its present earnings ratio. Plus, the 36-month beta value for EW is at 0.88. Opinions of the stock are interesting as 13 analysts out of 25 who provided ratings for Edwards Lifesciences Corporation declared the stock was a “buy,” while 1 rated the stock as “overweight,” 9 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $86.28, which is $3.87 above the current price. EW currently public float of 617.53M and currently shorts hold a 1.17% ratio of that float. Today, the average trading volume of EW was 2.62M shares.
EW’s Market Performance
EW stocks went down by -1.14% for the week, with a monthly jump of 6.92% and a quarterly performance of 20.11%, while its annual performance rate touched 14.67%. The volatility ratio for the week stands at 2.15% while the volatility levels for the past 30 days are set at 2.25% for Edwards Lifesciences Corporation. The simple moving average for the period of the last 20 days is 1.66% for EW stocks with a simple moving average of 13.32% for the last 200 days.
Analysts’ Opinion of EW
Many brokerage firms have already submitted their reports for EW stocks, with Wolfe Research repeating the rating for EW by listing it as a “Underperform.” The predicted price for EW in the upcoming period, according to Wolfe Research is $13 based on the research report published on September 11th of the current year 2020.
Wells Fargo, on the other hand, stated in their research note that they expect to see EW reach a price target of $230, previously predicting the value of $250. The rating they have provided for EW stocks is “Equal Weight” according to the report published on April 28th, 2020.
SVB Leerink gave a rating of “ Outperform” to EW, setting the target price at $270 in the report published on April 17th of the current year.
EW Trading at 7.22% from the 50-Day Moving Average
After a stumble in the market that brought EW to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.47% of loss for the given period.
Volatility was left at 2.25%, however, over the last 30 days, the volatility rate increased by 2.15%, as shares surge +6.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +22.31% upper at present.
During the last 5 trading sessions, EW fell by -1.14%, which changed the moving average for the period of 200-days by +2.72% in comparison to the 20-day moving average, which settled at $82.77. In addition, Edwards Lifesciences Corporation saw 7.85% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at EW starting from Ullem Scott B., who sold 33,150 shares at the price of $83.43 back on Sep 15. After this action, Ullem Scott B. now owns 27,114 shares of Edwards Lifesciences Corporation, valued at $2,765,748 using the latest closing price.
Ullem Scott B., the CVP, Chief Financial Officer of Edwards Lifesciences Corporation, sold 26,700 shares at $82.21 during a trade that took place back on Sep 14, which means that Ullem Scott B. is holding 27,114 shares at $2,194,908 based on the most recent closing price.
Stock Fundamentals for EW
Current profitability levels for the company are sitting at:
- +27.55 for the present operating margin
- +73.43 for the gross margin
The net margin for Edwards Lifesciences Corporation stands at +24.08. The total capital return value is set at 27.98, while invested capital returns managed to touch 24.53. Equity return is now at value 18.90, with 11.90 for asset returns.
Based on Edwards Lifesciences Corporation (EW), the company’s capital structure generated 16.36 points at debt to equity in total, while total debt to capital is 14.06. Total debt to assets is 10.46, with long-term debt to equity ratio resting at 43.88. Finally, the long-term debt to capital ratio is 15.75.
When we switch over and look at the enterprise to sales, we see a ratio of 11.19, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 7.65 and the total asset turnover is 0.74. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.31.